



## Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

September 4, 2020

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15<sup>th</sup> Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.

A live audio webcast of the presentation will be available [here](#) and on Arvinas' website at [www.arvinas.com](http://www.arvinas.com). A replay of the webcast will be archived on Arvinas' website for 30 days following the presentation.

### About Arvinas

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC<sup>®</sup> targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit [www.arvinas.com](http://www.arvinas.com).

### Contacts for Arvinas

#### Investors

Will O'Connor, Stern Investor Relations  
[ir@arvinas.com](mailto:ir@arvinas.com)

#### Media

Kirsten Owens, Arvinas Communications  
[kirsten.owens@arvinas.com](mailto:kirsten.owens@arvinas.com)